Get the Stockscreener App
8.14
10.32%
-0.835
Candel Therapeutics Inc stock is traded at $8.14, with a volume of 448.09K.
It is down -10.32% in the last 24 hours and up +12.57% over the past month.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.
See More
Previous Close:
$8.975
Open:
$9
24h Volume:
448.09K
Relative Volume:
0.12
Market Cap:
$388.27M
Revenue:
$124.00K
Net Income/Loss:
$-49.99M
P/E Ratio:
-4.8166
EPS:
-1.69
Net Cash Flow:
$-31.03M
1W Performance:
-26.56%
1M Performance:
+12.57%
6M Performance:
+27.55%
1Y Performance:
+373.45%
1-Day Range:
$8.03
$9.13
1-Week Range:
$8.03
$11.65
52-Week Range:
$1.34
$14.60
Candel Therapeutics Inc Stock (CADL) Company Profile
Name
Candel Therapeutics Inc
Sector
Industry
Phone
617-916-5445
Address
117 KENDRICK STREET, NEEDHAM
Compare CADL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CADL
Candel Therapeutics Inc
|
8.11 | 388.27M | 124.00K | -49.99M | -31.03M | -1.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
488.31 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.62 | 75.07B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
634.75 | 37.96B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
242.38 | 31.79B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
112.64 | 27.34B | 3.30B | -501.07M | 1.03B | -2.1146 |
Candel Therapeutics Inc Stock (CADL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-20-25 | Initiated | Citigroup | Buy |
| Feb-19-25 | Initiated | Canaccord Genuity | Buy |
| Feb-07-25 | Initiated | BofA Securities | Buy |
| Dec-02-22 | Initiated | H.C. Wainwright | Buy |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Aug-23-21 | Initiated | Credit Suisse | Outperform |
| Aug-23-21 | Initiated | Jefferies | Buy |
| Aug-23-21 | Initiated | UBS | Buy |
View All
Candel Therapeutics Inc Stock (CADL) Latest News
Top 5 Biotech Stocks That Saw Biggest Retail Following Jump Last Week - MSN
Candel Therapeutics (NASDAQ:CADL) Earns Buy Rating from HC Wainwright - MarketBeat
Candel Therapeutics CEO discusses promising Phase 2 pancreatic cancer trial resultsICYMI - Proactive financial news
Institutional investors in Candel Therapeutics, Inc. (NASDAQ:CADL) see US$153m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance
Insiders Enjoy US$1.3m Return After Buying Candel Therapeutics Stock - Simply Wall St
Canaccord Genuity Group Issues Positive Forecast for Candel Therapeutics (NASDAQ:CADL) Stock Price - MarketBeat
Candel reports extended survival in Phase II CAN-2409 trial - The Pharma Letter
Promising Potential of Candel Therapeutics’ CAN-2409: Analyst Recommends ‘Buy’ Based on Compelling Phase 2 Trial Results and Future Outlook - TipRanks
Candel Therapeutics reports Phase 2 trial shows extended survival in Pancreatic Cancer - Proactive Investors USA
Candel Therapeutics: I Say Stay The Course Despite The Market's Rebuke Of Positive Pancreatic Data - Seeking Alpha
Small cap headlines: Candel Therapeutics, Sintana Energy, Trust Stamp, Tiziana Life Sciences... - Proactive Investors UK
Candel Therapeutics stock drops despite OS improvement in PDAC trial - Yahoo Finance
Candel stock plunges 20% following Phase 2 data release - MSN
Candel Therapeutics Shares Fall After Final Pancreatic Cancer Survival Data -February 25, 2025 at 01:36 pm EST - Marketscreener.com
Candel stock plunges 20% following Phase 2 data release (CADL:NASDAQ) - Seeking Alpha
Candel Therapeutics Announces Positive Long-Term Survival Data From CAN-2409 Phase 2 Trial - Nasdaq
Candel Therapeutics reports significant survival benefit for pancreatic cancer therapy - Proactive Investors USA
Candel Therapeutics stock rises on positive trial data By Investing.com - Investing.com Australia
Candel Therapeutics stock rises on positive trial data - Investing.com
Candel Therapeutics Reports Positive Phase 2 Trial Results - TipRanks
Candel Therapeutics Reports Positive Final Survival Data for CAN-2409 in Borderline Resectable Pancreatic Cancer - Nasdaq
Candel Therapeutics Announces Positive Final Survival Data - GlobeNewswire
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 ... - Post Register
Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer - StockTitan
Candel Therapeutics (NASDAQ:CADL) Coverage Initiated at Citigroup - MarketBeat
(CADL) Trading Report - Stock Traders Daily
Candel Therapeutics (NASDAQ:CADL) Coverage Initiated at Canaccord Genuity Group - MarketBeat
Vontobel Holding Ltd. Sells 3,000 Shares of Candel Therapeutics, Inc. (NASDAQ:CADL) - Defense World
Citigroup Begins Coverage on Candel Therapeutics (NASDAQ:CADL) - Defense World
Candel Therapeutics Inc (CADL) Forecast: Revisiting The Past To Gain Insights For The Future - Stocks Register
Citi sets $25 target on Candel Therapeutics stock with Buy rating By Investing.com - Investing.com South Africa
Candel Therapeutics, Inc. (NASDAQ:CADL) Sees Large Decline in Short Interest - MarketBeat
This Palantir Technologies Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday - Benzinga
Candel Therapeutics Inc (CADL) Stock: A 52-Week Tale of Drops and Gains - The InvestChronicle
Candel Therapeutics: Entering Its Pivotal Year (NASDAQ:CADL) - Seeking Alpha
Citigroup Initiates Candel Therapeutics at Buy With $25 Price Target -February 20, 2025 at 07:39 am EST - Marketscreener.com
Citigroup Initiates Coverage of Candel Therapeutics (CADL) with Buy Recommendation - Nasdaq
Candel Therapeutics Stock Rallies On Canaccord’s Vote Of Confidence In Lead Cancer Drug: Retail Traders Rejoice - MSN
Citi sets $25 target on Candel Therapeutics stock with Buy rating - Investing.com India
Candel Therapeutics (NASDAQ:CADL) Now Covered by Analysts at Canaccord Genuity Group - Defense World
Candel Therapeutics Stock Rallies On Canaccord’s Vote Of Confidence In Lead Cancer Drug: Retail Traders Rejoic - Asianet Newsable
This GE Vernova Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
Candel Therapeutics, Inc. (NASDAQ:CADL) Short Interest Update - Defense World
Analysts Say Candel Therapeutics Inc (NASDAQ: CADL) Should Remain On Your Watch List - Stocks Register
Trend Tracker for (CADL) - Stock Traders Daily
Insider Sale Alert: Candel Therapeutics Inc [CADL] – Is it Time to sell? - Knox Daily
Candel Therapeutics (NASDAQ:CADL) Coverage Initiated at Bank of America - MarketBeat
Candel Therapeutics (NASDAQ:CADL) Earns Buy Rating from Analysts at Bank of America - Defense World
Candel Therapeutics Inc (CADL) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Candel Therapeutics Inc (CADL) Stock: Evaluating the Annual Growth - The News Heater
Candel Therapeutics Stock Headed For 20% Weekly Gains: Retail Over The Moon With BofA's 'Buy' Call - MSN
Candel Therapeutics Inc Stock (CADL) Financials Data
Revenue
Net Income
Cash Flow
EPS
Candel Therapeutics Inc Stock (CADL) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Tyagarajan Seshu | Chief Technology Officer |
Jan 15 '25 |
Sale |
7.22 |
14,322 |
103,476 |
96,790 |
| Schoch Charles | See Remarks |
Jan 15 '25 |
Sale |
7.22 |
9,511 |
68,717 |
43,038 |
| Tak Paul Peter | Chief Executive Officer |
Jan 15 '25 |
Sale |
7.22 |
21,704 |
156,811 |
251,912 |
| Nichols William Garrett | Chief Medical Officer |
Jan 15 '25 |
Sale |
7.22 |
10,428 |
75,342 |
79,320 |
3.91%
1.68%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):